iShares Nasdaq Biotechnology ETF (IBB) Position Reduced by Usca Ria LLC

Usca Ria LLC decreased its stake in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 70.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,550 shares of the financial services provider’s stock after selling 5,984 shares during the quarter. Usca Ria LLC’s holdings in iShares Nasdaq Biotechnology ETF were worth $246,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in IBB. State of Tennessee Treasury Department bought a new position in iShares Nasdaq Biotechnology ETF in the 4th quarter valued at $40,732,000. Lockheed Martin Investment Management Co. raised its position in iShares Nasdaq Biotechnology ETF by 173.9% in the 4th quarter. Lockheed Martin Investment Management Co. now owns 417,400 shares of the financial services provider’s stock valued at $40,250,000 after purchasing an additional 265,000 shares during the last quarter. Credit Suisse AG raised its position in iShares Nasdaq Biotechnology ETF by 1,228.8% in the 3rd quarter. Credit Suisse AG now owns 224,782 shares of the financial services provider’s stock valued at $27,410,000 after purchasing an additional 207,866 shares during the last quarter. Alliancebernstein L.P. raised its position in iShares Nasdaq Biotechnology ETF by 36.2% in the 3rd quarter. Alliancebernstein L.P. now owns 737,179 shares of the financial services provider’s stock valued at $89,892,000 after purchasing an additional 195,746 shares during the last quarter. Finally, Morgan Stanley raised its position in iShares Nasdaq Biotechnology ETF by 3.7% in the 3rd quarter. Morgan Stanley now owns 4,026,110 shares of the financial services provider’s stock valued at $490,944,000 after purchasing an additional 143,209 shares during the last quarter. 64.40% of the stock is currently owned by institutional investors and hedge funds.

Shares of IBB stock traded down $0.63 on Thursday, reaching $109.24. 135,686 shares of the stock were exchanged, compared to its average volume of 2,130,648. iShares Nasdaq Biotechnology ETF has a one year low of $89.01 and a one year high of $122.97.

TRADEMARK VIOLATION NOTICE: “iShares Nasdaq Biotechnology ETF (IBB) Position Reduced by Usca Ria LLC” was first published by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.themarketsdaily.com/2019/03/07/ishares-nasdaq-biotechnology-etf-ibb-position-reduced-by-usca-ria-llc.html.

iShares Nasdaq Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

See Also: The Structure of a Futures Contract

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.